Difference between revisions of "Craniopharyngioma"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
Warner-admin (talk | contribs) m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | {{#lst: | + | {{#lst:Editorial board transclusions|neuro}} |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 12: | Line 12: | ||
=Guidelines= | =Guidelines= | ||
| − | == | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
| − | *''NCCN does not have guidelines at this granular level; please go to the [[:Category:CNS cancers|Central Nervous System Cancers category page]].'' | + | ==NCCN== |
| + | *''NCCN does not currently have guidelines at this granular level; please go to the [[:Category:CNS cancers|Central Nervous System Cancers category page]].'' | ||
=All lines of therapy= | =All lines of therapy= | ||
| Line 24: | Line 25: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464854/ Brastianos et al. 2023 (Alliance A071601)] |
| − | | | + | |2018-02-20 to 2020-03-31 |
| style="background-color:#91cf61" |Phase 2 | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
| Line 37: | Line 38: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
| − | *[[Cobimetinib (Cotellic)]] | + | *[[Cobimetinib (Cotellic)]] 60 mg PO once per day on days 1 to 21 |
| − | *[[Vemurafenib (Zelboraf)]] | + | *[[Vemurafenib (Zelboraf)]] 960 mg PO twice per day on days 1 to 28 |
'''28-day cycles''' | '''28-day cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''Alliance A071601:''' Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. | + | # '''Alliance A071601:''' Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. [https://doi.org/10.1056/nejmoa2213329 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464854/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37437144/ PubMed] [https://clinicaltrials.gov/study/NCT03224767 NCT03224767] |
| − | [https://doi.org/10.1056/nejmoa2213329 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37437144/ PubMed] [https://clinicaltrials.gov/study/NCT03224767 NCT03224767] | ||
[[Category:Craniopharyngioma regimens]] | [[Category:Craniopharyngioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:CNS cancers]] | [[Category:CNS cancers]] | ||
Latest revision as of 12:17, 15 July 2024
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please go to the Central Nervous System Cancers category page.
All lines of therapy
Cobimetinib & Vemurafenib
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Brastianos et al. 2023 (Alliance A071601) | 2018-02-20 to 2020-03-31 | Phase 2 |
Eligibility criteria
- Histology: Papillary
Biomarker eligibility criteria
- BRAF mutation
Targeted therapy
- Cobimetinib (Cotellic) 60 mg PO once per day on days 1 to 21
- Vemurafenib (Zelboraf) 960 mg PO twice per day on days 1 to 28
28-day cycles
References
- Alliance A071601: Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT03224767